Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul;9(14):1148. doi: 10.21037/atm-21-2589

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

The frequency of M-MDSCs in peripheral blood of cancer patients and healthy donors. (A) CD14⁺HLA-DR⁻ M-type MDSCs were significantly elevated in patients relative to healthy donors (mean 9.01% vs. 2.63%, P<0.0001). (B) A significant positive correlation was observed between healthy donors and patients with different stage (mean 2.06% vs. 7.55%, 9.97% and 10.17% for healthy vs. stage I, II and III; P<0.0001, P<0.0001, P<0.0001 respectively). No correlation between the M-MDSCs and TNM stage (C) or tumor differentiation (D) stage. * indicates a P value of <0.05; *** indicates a P value of <0.0001. MDSCs, myeloid-derived suppressor cells; M-MDSCs, monocytic myeloid-derived suppressor cells; TNM, tumor, node, metastasis; Health, healthy volunteers; Patients, HNSCC patients.